PART I Overview BioVie Inc. (the Company or we or our) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. Neurodegenerative Disease Program The Company acquired the biopharmaceutical assets of NeurMedix, Inc. (NeurMedix) a privately held clinical-stage pharmaceutical company and a related party in June 2021.The acquired assets included NE3107 (or bezisterim). Bezisterim, the approved gener...
Q2 FY2026 — expected 2026-08-23
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-08-15 | 2025-06-30 | 0001520138-25-000268 | EDGAR | 56K words |
| 2024-09-30 | 2024-06-30 | 0001520138-24-000324 | EDGAR | — |
| 2023-08-16 | 2023-06-30 | 0001520138-23-000325 | EDGAR | — |
| 2022-09-27 | 2022-06-30 | 0001520138-22-000437 | EDGAR | — |
| 2021-08-30 | 2021-06-30 | 0001520138-21-000509 | EDGAR | — |
| 2020-08-06 | 2020-06-30 | 0001520138-20-000356 | EDGAR | — |
| 2019-09-27 | 2019-06-30 | 0001520138-19-000336 | EDGAR | — |
| 2018-10-05 | 2018-06-30 | 0001520138-18-000269 | EDGAR | — |
| 2017-08-24 | 2017-06-30 | 0001520138-17-000286 | EDGAR | — |
| 2016-09-28 | 2016-06-30 | 0001520138-16-001180 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-06 | 2025-12-31 | 0001520138-26-000052 | EDGAR | 20K words |
| 2025-11-10 | 2025-09-30 | 0001520138-25-000343 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001520138-25-000144 | EDGAR | — |
| 2025-02-11 | 2024-12-31 | 0001520138-25-000056 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001520138-24-000425 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001520138-24-000204 | EDGAR | — |
| 2024-02-13 | 2023-12-31 | 0001520138-24-000069 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001520138-23-000473 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001520138-23-000227 | EDGAR | — |
| 2023-02-10 | 2022-12-31 | 0001520138-23-000087 | EDGAR | — |
| 2022-11-04 | 2022-09-30 | 0001520138-22-000502 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001520138-22-000201 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-11-13 | 0001520138-25-000352 | EDGAR | 1K words |
| 2025-11-12 | 0001520138-25-000347 | EDGAR | — |
| 2025-08-11 | 0001520138-25-000249 | EDGAR | — |
| 2025-07-23 | 0001520138-25-000223 | EDGAR | — |
| 2025-06-27 | 0001520138-25-000190 | EDGAR | — |
| 2025-06-24 | 0001520138-25-000185 | EDGAR | — |
| 2025-03-28 | 0001520138-25-000089 | EDGAR | — |
| 2024-11-08 | 0001520138-24-000410 | EDGAR | — |
| 2024-10-29 | 0001520138-24-000404 | EDGAR | — |
| 2024-10-29 | 0001520138-24-000400 | EDGAR | — |
201 total filings indexed. 169 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001580149 |
| Ticker | BIVI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.bioviepharma.com |
| Listed | 2014-01-14 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report